---
schema_version: "secwatch.filing_event.v1"
accession: "0001213900-24-013668"
form_type: "8-K"
ticker: "ALLR"
cik: "0001860657"
company_name: "Allarity Therapeutics, Inc."
filed_at: "2024-02-14T23:59:59+00:00"
generated_at: "2026-06-06T02:38:11.406847+00:00"
event_type: "debt"
sentiment: "neutral"
materiality_score: 0.5
calibrated_materiality_score: 0.5
confidence: "high"
source: SEC EDGAR
---

# Allarity Therapeutics issues $440K convertible note to 3i, LP; amends Series A conversion price to $0.405

## Summary
- Second closing of $440K principal senior convertible note purchased for $400K (10% original issue discount), due February 2025.
- Note carries 8% annual interest, convertible at $0.405 per share; Purchaser limited to 4.99% beneficial ownership cap.
- Limited Waiver Agreement permits second closing before the 30-day waiting period required by the original purchase agreement.
- Conversion price of Series A Preferred Stock amended from $0.4476 to $0.405 via Sixth Certificate of Amendment filed with Delaware.
- Net proceeds to be used for accounts payable and working capital; negative covenants restrict additional indebtedness over $250K.

## SEC filing metadata
- accession: 0001213900-24-013668
- form_type: 8-K
- ticker: ALLR
- cik: 0001860657
- company_name: Allarity Therapeutics, Inc.
- filed_at: 2024-02-14T23:59:59+00:00
- event_type: debt
- sentiment: neutral
- materiality_score: 0.5
- calibrated_materiality_score: 0.5
- confidence: high
- sec_items: 1.01, 2.03, 3.02, 3.03, 5.03, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1860657/000121390024013668/0001213900-24-013668-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1860657/000121390024013668/ea193650-8k_allarity.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001213900-24-013668
- JSON: https://secwatch.observer/filing/0001213900-24-013668.json
- Plain text: https://secwatch.observer/filing/0001213900-24-013668.txt

## Key facts
- Debt Financings
  Allarity Therapeutics, Inc. incurred convertible notes of $440,000 with 3i, LP at 8% per annum maturing 2025-02-13.
  - Instrument: convertible notes
  - Principal: $440,000
  - Counterparty: 3i, LP
  - Rate: 8% per annum
  - Maturity: 2025-02-13
  - Event: incurrence
  source text: we issued and sold to the Purchaser a senior convertible promissory note in an aggregate principal amount of $440,000 (the “Principal Amount”) due on February 13, 2025
  evidence_url: https://www.sec.gov/Archives/edgar/data/1860657/000121390024013668/0001213900-24-013668-index.htm
- Governance Changes
  Allarity Therapeutics, Inc.: Amended Series A Preferred Stock conversion price from $0.4476 to $0.405 via Sixth Certificate of Amendment (effective 2024-02-13).
  - Change: charter amendment
  - Effective: 2024-02-13
  source text: On February 13, 2024, we filed the Sixth Amendment to change the “Conversion Price” from $0.4476 to $0.405.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1860657/000121390024013668/0001213900-24-013668-index.htm
- Material Agreements
  Allarity Therapeutics, Inc. entered into Limited Waiver Agreement and Second Convertible Promissory Note with 3i, LP valued at $440,000 principal, $400,000 purchase price, 8% interest, convertible at $0.405/share (effective 2024-02-13).
  - Action: entry
  - Agreement: credit facility
  - Counterparty: 3i, LP
  - Value: $440,000 principal, $400,000 purchase price, 8% interest, convertible at $0.405/share
  - Effective: 2024-02-13
  source text: On February 13, 2024 (the “Second Closing”), the Parties entered into a Limited Waiver Agreement (the “Waiver Agreement”) and agreed that the Second Closing can be consummated prior to the 30 th calendar day following January 18, 2024.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1860657/000121390024013668/0001213900-24-013668-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.